Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00904579 · ClinicalTrials.gov registry record

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
19,929,901
Enrollment target

NCT00904579: Completed study, sponsored by National Cancer Institute (NCI).

NCT00904579 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 19,929,901 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00904579 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
19,929,901 participants
Enrollment target

Study Summary

Background: * Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression * End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to transplant, is itself linked to increased risk for some cancers * The role of immunosuppression and other factors causing cancer in this setting are not fully understood. Objectives: * To characterize cancer risk in transplant recipients and identify risk factors. * To characterize risk for transmission of cancer from organ donors to recipients. * To describe cancer risk in ESRD. Eligibility: Patients are not required for this study. Data are gathered from existing databases of ESRD patients, organ transplant patients and cancer registries. Design: * Databases of 1) U.S. transplant recipients, donors and wait list candidates and 2) U.S. ESRD patients will be linked to multiple U.S. cancer registries to identify cancers in transplant recipients and ESRD patients. * The spectrum of cancer risk in transplant recipients and ESRD patients will be evaluated in detail. * The cancer risk in transplant recipients will be examined in relation to whether the donors had cancer. * The proposed cancer risk factors (e.g., underlying medical condition, infection with cancer-causing viruses, immunosuppressive medications) documented in transplant and ESRD files will be studied for association with increased risk of particular types of cancer.

Primary Outcome

Cancer patients who have had organ transplants identified through the transplant and cancer registries.

Trial Details

FieldValue
Enrollment Target 19,929,901 participants
Start Date 2006-07-01
Est. Completion 2020-04-22
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00904579 record still lists

NCT00904579 is an observational study that tracks outcomes without assigning an intervention. Its 19,929,901 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00904579 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00904579 about?

NCT00904579 is a clinical study titled "Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease". Background: * Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression * End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to trans...

What is the current status of trial NCT00904579?

This trial is currently completed. The enrollment target is 19,929,901 participants. The study started on 2006-07-01. Estimated completion is 2020-04-22.

Who is sponsoring clinical trial NCT00904579?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02485847 · 20,000,000 participants

    IRIS Registry: Intelligent Research in Sight Registry

  • NCT05678699 · 10,000,000 participants · NA

    The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity

  • NCT02693223 · 3,892,063 participants

    Get With the Guidelines-Stroke Registry

  • NCT06803498 · 3,000,000 participants

    Delivery Room Intervention and Evaluation Network

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00904579, the US trial registry maintained by the National Library of Medicine. NCT00904579 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.